Today, the drug target recommended by KMD Bioscience is PD-1/PD-L1 (Programmed Death-1/Ligand-1)

Background: PD-1, a checkpoint inhibitor found on the surface of T cells, and its ligand, PD-L1, play crucial roles in suppressing the immune response, allowing cancer cells to evade immune detection. Targeting the PD-1/PD-L1 pathway with recombinant antibodies can reactivate the immune system to recognize and destroy cancer cells.

Therapeutic Application: Used in immuno-oncology to treat various cancers, including melanoma, lung cancer, and kidney cancer, PD-1/PD-L1 inhibitors have revolutionized cancer therapy, offering hope for previously untreatable cases.

KMD Bioscience has many years of experience in the research of monoclonal antibody drugs. KMD Bioscience has gathered a group of scientists with advanced technology in the field of monoclonal antibodies, committed to providing excellent services for customer drug research. Our monoclonal antibody drugs are developed using recombinant antibody technology, using the same sequence as therapeutic antibodies and tested to ensure specific binding with the same target molecules, making them a suitable choice for drug research or analytical development. All the antibody products we provide have undergone strict QC verification, and all antibodies have undergone strict testing to ensure high purity and quality. At the same time, experts in the research field of KMD Bioscience have been searching for novel targets and are committed to providing customers with diverse antibody products.

KMD Bioscience has independently developed various monoclonal antibody drugs targeting different targets. KMD Bioscience monoclonal antibody drugs are only used for scientific research and cannot be used for other purposes.


About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2024 MolecularCloud